What question did this study set out to answer?

To compare the effects of as-needed albuterol-budesonide versus albuterol on asthma control and exacerbation risk in patients with mild asthma.

B22-23 Albuterol-budesonide Rescue Enhances Improvements in Control Compared With Albuterol Rescue for Patients With Mild Asthma

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial finds improved asthma control and reduced exacerbation risk in mild asthma with albuterol-budesonide compared to albuterol alone.

To compare the effects of as-needed albuterol-budesonide versus albuterol on asthma control and exacerbation risk in patients with mild asthma.
Enrolled patients aged ≥12 years using SABA rescue ± low-dose inhaled corticosteroid or leukotriene receptor antagonist maintenance.
Randomized treatment for patients aged ≥18 years using either as-needed albuterol-budesonide or albuterol for at least 28 weeks.
Cox proportional hazards model assessed time-to-first exacerbation risk reduction over 16 and 28 weeks.
As-needed albuterol-budesonide showed a 43% reduction in severe exacerbation risk at 16 weeks and 51% at 28 weeks.
Patients using albuterol-budesonide had 29% and 21% higher odds of achieving well-controlled asthma at 16 and 28 weeks, respectively.
The odds of baseline very poorly controlled asthma becoming well-controlled was 50% greater with albuterol-budesonide at 16 weeks.

Papi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial finds improved asthma control and reduced exacerbation risk in mild asthma with albuterol-budesonide compared to albuterol alone.

To compare the effects of as-needed albuterol-budesonide versus albuterol on asthma control and exacerbation risk in patients with mild asthma.
Enrolled patients aged ≥12 years using SABA rescue ± low-dose inhaled corticosteroid or leukotriene receptor antagonist maintenance.
Randomized treatment for patients aged ≥18 years using either as-needed albuterol-budesonide or albuterol for at least 28 weeks.
Cox proportional hazards model assessed time-to-first exacerbation risk reduction over 16 and 28 weeks.
As-needed albuterol-budesonide showed a 43% reduction in severe exacerbation risk at 16 weeks and 51% at 28 weeks.
Patients using albuterol-budesonide had 29% and 21% higher odds of achieving well-controlled asthma at 16 and 28 weeks, respectively.
The odds of baseline very poorly controlled asthma becoming well-controlled was 50% greater with albuterol-budesonide at 16 weeks.

Papi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark